VN August 2026

Vetnews | Augustus 2026 40 « BACK TO CONTENTS Every year, members from our hospital [Johannesburg and Cape Animal Eye Hospital] make a point of attending the European College of Veterinary Ophthalmology (ECVO) congress. This congress is hosted annually by the ECVO and attracts veterinary ophthalmologists and other professionals interested in veterinary ophthalmology from around the world. It has become the premier event on the veterinary ophthalmology academic calendar. This year, in Madrid, was no exception. The congress has a whole day of master classes on a specified topic before the three-day academic research component begins. This year the topic was ocular pharmacology. There is currently much research being done in this area, and the concepts presented at this congress are so important to veterinarians that I felt it was essential to share these with our South African colleagues. These principles can be adopted immediately in our consulting rooms. Much of what we know in clinical veterinary ophthalmology pharmacology may be based on hearsay or even concepts handed down and have become urban legends. There is a renewed emphasis on research to confirm some very basic principles on how we make use of eye medications. Much of the current knowledge is taken from pharmacological studies done on healthy eyes and not pathologic cases. Our patients have ocular pathology. A further problem is that much of the research was also done on rabbits, small rodents and other laboratory species, and it may be incorrect to extrapolate results to cats and dogs. A simple concept to consider is that the blink rate in rabbits is once every 10-20 mins and so data collected in rabbits may be profoundly different to that in other species. Small rodent eyes may have a very different ability to manage dose volume in small eyes and the ability to penetrate the cornea. Recent research is now describing the Blood-Tear-Barrier [BTB] as an extremely important structure that affects the way we need to manage ocular pharmacology. There are tight junctions between the conjunctival cells, allowing stabilisation of the ocular surface, but when the tissue is inflamed and congested [conjunctivitis], there is a breakdown of the tight junctions and measurable amounts of albumin may leak to the ocular surface and be present in the tear film. This albumin in the tears may increase 2.7-14 fold the levels in the healthy eye. With conjunctivitis, this breakdown of the BTB also enhances the permeability of the ocular surface, resulting in increased absorption of products placed on the ocular surface. Let’s look at the first concept of increased albumin in the tear film. It is now shown that the albumin in the tear film will bind to the medication and reduce the bioavailability of the administered medication. The percentage of binding varies between products but is at least 8%. When we consider the application of an antibiotic eyedrop to the eye, it appears that only the unbound component of the antibiotic drop is microbiologically active. This may have significant effects on the minimum inhibitory concentration [MIC] for specific bacteria and affect the efficacy of the medication that is being applied or the frequency with which one must apply it in order for it to be effective. Regulars I Ophthalmology Column Ocular Pharmacology Dr Anthony Goodhead Johannesburg and Cape Animal Eye Hospitals www.animaleyehospital.co.za

RkJQdWJsaXNoZXIy OTc5MDU=